Aslan Pharmaceuticals to host KOL panel discussion on Dupilumab

ASLAN Pharmaceuticals announced that it will host a virtual Key Opinion Leader, KOL, Event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market.” The event will feature a discussion with Lisa Beck, MD from University of Rochester, Peter Lio, MD from Northwestern University, and Raj Chovatiya, MD, PhD from Rosalind Franklin University Chicago Medical School, moderated by Seth Orlow, MD, PhD from New York University, on the recently announced positive interim results from ASLAN’s Phase 2 TREK-DX study of eblasakimab, a potential first-in-class biologic candidate, in patients with moderate-to-severe atopic dermatitis that had previously been treated with dupilumab. Panelists will discuss this growing new market and the treatment options available to patients with an inadequate response to dupilumab. Company management will also present new data from the interim analysis of the TREK-DX study.